Yulia Sh. Prints
Yulia Sh. Prints has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Igor V. Zhirov
E.I. Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
6 shared publications - Oleg M. Reitblat
Regional Clinical Hospital № 1
6 shared publications - Sergey Tereshchenko
Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
6 shared publications - Anna A. Airapetian
Chazov National Medical Research Center of Cardiology
4 shared publications - Evgeny M. Mezhonov
Tyumen State Medical University; Regional Clinical Hospital №1
4 shared publications - Natalia V. Lazareva
Chazov National Medical Research Center of Cardiology
4 shared publications
Latest Publications
- 2 April 2026
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 21 (1)
Treatment efficacy and adherence in patients with chronic heart failure according to the chronic heart failure registry in the Tyumen region
The objective of the study was to evaluate achievement of target doses of essential medications (ACE inhibitors/ARBs/ARNIs, beta-blockers, MRA and SGLT2) and patient adherence to therapy. We analyzed medication prescriptions depending on CHF phenotype and left ventricular ejection fraction (LVEF), as well as dynamics of clinical and laboratory parameters (LVEF and NT-proBNP). There was low rate of achievement of target doses for beta-blockers and ACE inhibitors/ARBs/ARNIs (<20% of patients), while MRAs were prescribed at optimal doses in more than 90% of cases. Only 50.6% of patients demonstrated high adherence to therapy. Repeated assessment of LVEF and NTproBNP was performed in only a subset of patients. However, patients on optimal medical therapy showed improvements of LVEF and decrease of NTproBNP. Therefore, it is necessary to increase physician awareness, improve compliance with clinical guidelines and intensify follow-up to improve treatment adherence and prognosis in patients with CHF.
- 2 April 2026
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 21 (1)
Treatment efficacy and adherence in patients with chronic heart failure according to the chronic heart failure registry in the Tyumen region
The objective of the study was to evaluate achievement of target doses of essential medications (ACE inhibitors/ARBs/ARNIs, beta-blockers, MRA and SGLT2) and patient adherence to therapy. We analyzed medication prescriptions depending on CHF phenotype and left ventricular ejection fraction (LVEF), as well as dynamics of clinical and laboratory parameters (LVEF and NT-proBNP). There was low rate of achievement of target doses for beta-blockers and ACE inhibitors/ARBs/ARNIs (<20% of patients), while MRAs were prescribed at optimal doses in more than 90% of cases. Only 50.6% of patients demonstrated high adherence to therapy. Repeated assessment of LVEF and NTproBNP was performed in only a subset of patients. However, patients on optimal medical therapy showed improvements of LVEF and decrease of NTproBNP. Therefore, it is necessary to increase physician awareness, improve compliance with clinical guidelines and intensify follow-up to improve treatment adherence and prognosis in patients with CHF.
- Open Access
- 30 July 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (7) , 666-674
Chronic kidney disease and chronic heart failure: impact on prognosis and choice of pathogenetic therapy
Aim. To evaluate the impact of a decrease in glomerular filtration rate (GFR) on the prognosis of patients with chronic heart failure (CHF), to analyze real clinical practice regarding the frequency of prescribing pathogenetic therapy for CHF, achieving target dosages depending on the gradation of GFR in patients included in the CHF Register of the Tyumen region. Materials and methods. The analysis included medical data of 4077 patients (1662 men and 2415 women) with NYHA class I–IV CHF who underwent examination and treatment in medical organizations of the Tyumen region for the period from January 2020 to May 2023. Criteria for inclusion in the register: proven heart failure. Chronic kidney disease (CKD) was assessed by GFR calculated using the CKD-EPI formula (ml/min/1.73 m2). The primary end point was defined as death from all causes. Results. GFR60 ml/min/1.73 m2 was recorded in 34.6% of patients, more common in women (40.2 and 26.6%, respectively; p0.001). When dividing patients into phenotypes according to LVEF, no statistically significant differences were found in the distribution of patients according to GFR. In patients with HFrEF and HFpEF GFR45 ml/min/1.73 m2 was associated with an increased risk of meeting the endpoint. Analysis of prescribed pathogenetic therapy showed that in patients with HFrEF, the frequency of prescription of ACE inhibitors, â-blockers and MRA decreased (p=0.023, 006 and 0.01, respectively), and ARNI, on the contrary, increased with a decrease in GFR (p=0.026). In patients with HFpEF, a similar trend towards a decrease in the frequency of prescription of ACEIs and MCBs with a decrease in GFR (p0.001) remained, but it was compensated by an inversely proportional increase in the frequency of prescription of ARBs (p0.001). 100% of the target dosage is achieved in more than 90% of patients taking MRA across the entire LVEF range. While for â-blockers and ARNI/ACE/ARB the percentage of patients receiving the full therapeutic dosage of drugs is significantly lower. When analyzing target dosages of pathogenetic drugs, gradations of achieved doses were distributed evenly throughout the entire range of GFR. Conclusion. GFR60 ml/min/1.73 m2 occurs in every 3 patients with CHF across the entire range of LVEF. A decrease in GFR worsens the prognosis of patients with both HFrEF and HFpEF, increasing in direct proportion with the severity of the stage of CKD. Inclusion of patients in the monitoring program within the framework of the CHF service allows the treatment to be significantly brought closer to optimal drug therapy, at the same time, certain efforts are required to overcome difficulties with titration to target dosages.
- 30 July 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (7) , 666-674
Open AccessChronic kidney disease and chronic heart failure: impact on prognosis and choice of pathogenetic therapy
Aim. To evaluate the impact of a decrease in glomerular filtration rate (GFR) on the prognosis of patients with chronic heart failure (CHF), to analyze real clinical practice regarding the frequency of prescribing pathogenetic therapy for CHF, achieving target dosages depending on the gradation of GFR in patients included in the CHF Register of the Tyumen region. Materials and methods. The analysis included medical data of 4077 patients (1662 men and 2415 women) with NYHA class I–IV CHF who underwent examination and treatment in medical organizations of the Tyumen region for the period from January 2020 to May 2023. Criteria for inclusion in the register: proven heart failure. Chronic kidney disease (CKD) was assessed by GFR calculated using the CKD-EPI formula (ml/min/1.73 m2). The primary end point was defined as death from all causes. Results. GFR60 ml/min/1.73 m2 was recorded in 34.6% of patients, more common in women (40.2 and 26.6%, respectively; p0.001). When dividing patients into phenotypes according to LVEF, no statistically significant differences were found in the distribution of patients according to GFR. In patients with HFrEF and HFpEF GFR45 ml/min/1.73 m2 was associated with an increased risk of meeting the endpoint. Analysis of prescribed pathogenetic therapy showed that in patients with HFrEF, the frequency of prescription of ACE inhibitors, â-blockers and MRA decreased (p=0.023, 006 and 0.01, respectively), and ARNI, on the contrary, increased with a decrease in GFR (p=0.026). In patients with HFpEF, a similar trend towards a decrease in the frequency of prescription of ACEIs and MCBs with a decrease in GFR (p0.001) remained, but it was compensated by an inversely proportional increase in the frequency of prescription of ARBs (p0.001). 100% of the target dosage is achieved in more than 90% of patients taking MRA across the entire LVEF range. While for â-blockers and ARNI/ACE/ARB the percentage of patients receiving the full therapeutic dosage of drugs is significantly lower. When analyzing target dosages of pathogenetic drugs, gradations of achieved doses were distributed evenly throughout the entire range of GFR. Conclusion. GFR60 ml/min/1.73 m2 occurs in every 3 patients with CHF across the entire range of LVEF. A decrease in GFR worsens the prognosis of patients with both HFrEF and HFpEF, increasing in direct proportion with the severity of the stage of CKD. Inclusion of patients in the monitoring program within the framework of the CHF service allows the treatment to be significantly brought closer to optimal drug therapy, at the same time, certain efforts are required to overcome difficulties with titration to target dosages.
- Open Access
- 3 November 2023
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 95 (9) , 739-745
Creation of registers as one of the mechanisms for improving medical care for patients with chronic heart failure. Problem state
The annual mortality of patients with clinically pronounced symptoms of chronic heart failure in the Russian Federation reaches 2629%, i.e., from 880 to 986 thousand patients with heart failure die in the country in one year, which is comparable to the population of a large city. Providing care for patients with heart failure places a heavy burden on the country's health care system, making a significant contribution to mortality rates, hospitalization rates, including readmissions, which in turn requires considerable costs. The article presents an overview of registry studies that are devoted to assessing the effectiveness of diagnostics, the completeness of examinations, as well as the adequacy of ongoing drug treatment.
- 3 November 2023
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 95 (9) , 739-745
Open AccessCreation of registers as one of the mechanisms for improving medical care for patients with chronic heart failure. Problem state
The annual mortality of patients with clinically pronounced symptoms of chronic heart failure in the Russian Federation reaches 2629%, i.e., from 880 to 986 thousand patients with heart failure die in the country in one year, which is comparable to the population of a large city. Providing care for patients with heart failure places a heavy burden on the country's health care system, making a significant contribution to mortality rates, hospitalization rates, including readmissions, which in turn requires considerable costs. The article presents an overview of registry studies that are devoted to assessing the effectiveness of diagnostics, the completeness of examinations, as well as the adequacy of ongoing drug treatment.
- Open Access
- 15 October 2023
- Published by Consilium Medicum in Consilium Medicum
- Vol. 25 (10) , 685-692
Comorbid conditions in patients with chronic heart failure (according to the registry of chronic heart failure in the Tyumen region)
Background. Comorbidity in patients with chronic heart failure (CHF) makes a major impact to the course of both the underlying and concomitant diseases, significantly worsens the prognosis and increases mortality from cardiovascular diseases. Improving specialized treatment within the framework of a three-tier model of providing medical care to patients with CHF is a healthcare priority. Aim. Analysis of the frequency of comorbid conditions in patients with CHF included in the CHF registry in the Tyumen region. Materials and methods. The study was conducted using the CHF register method, which has been operating in the Tyumen region since January 2020. Medical data from outpatient cards and discharge reports were entered by doctors from 9 polyclinics with an attached population, 1 consultative polyclinic, hospitals, on the basis of which there are outpatient CHF rooms in the structure of polyclinics in the city of Tobolsk, Zavodoukovsk, with. Nizhnyaya Tavda, Yalutorovsk, Tyumen Region, Ural Federal District. The study included medical data of 5741 patients with CHF I–IV functional classes (FC). Gender, clinical-instrumental and laboratory data, non-cardiac and cardiac diseases according to the International Classification of Diseases of the 10th revision were entered into a single map of the CHF registry. Results. In the study sample of patients with CHF, whose average age was 70.0±9.7 years, 2331 (40.6%) were men and 3410 (59.4%) were women. The most common cardiovascular diseases were: coronary artery disease – 55.4%, HD – 22.5% and HRT – 13.5% of cases. Among concomitant diseases of non-cardiac reasons, diabetes mellitus was most often noted – in 31.5% of cases, chronic kidney disease – in 31.1% and chronic obstructive pulmonary disease – in 10% of cases. Concomitant diseases were more common in patients with CHF of functional classes III–IV. Conclusion. Maintaining a register of CHF and analyzing register data makes it possible to assess the required volume of medical care, plan the necessary time, material, economic and organizational resources and take into account possible difficulties in diagnosis, treatment and outpatient monitoring.
- 15 October 2023
- Published by Consilium Medicum in Consilium Medicum
- Vol. 25 (10) , 685-692
Open AccessComorbid conditions in patients with chronic heart failure (according to the registry of chronic heart failure in the Tyumen region)
Background. Comorbidity in patients with chronic heart failure (CHF) makes a major impact to the course of both the underlying and concomitant diseases, significantly worsens the prognosis and increases mortality from cardiovascular diseases. Improving specialized treatment within the framework of a three-tier model of providing medical care to patients with CHF is a healthcare priority. Aim. Analysis of the frequency of comorbid conditions in patients with CHF included in the CHF registry in the Tyumen region. Materials and methods. The study was conducted using the CHF register method, which has been operating in the Tyumen region since January 2020. Medical data from outpatient cards and discharge reports were entered by doctors from 9 polyclinics with an attached population, 1 consultative polyclinic, hospitals, on the basis of which there are outpatient CHF rooms in the structure of polyclinics in the city of Tobolsk, Zavodoukovsk, with. Nizhnyaya Tavda, Yalutorovsk, Tyumen Region, Ural Federal District. The study included medical data of 5741 patients with CHF I–IV functional classes (FC). Gender, clinical-instrumental and laboratory data, non-cardiac and cardiac diseases according to the International Classification of Diseases of the 10th revision were entered into a single map of the CHF registry. Results. In the study sample of patients with CHF, whose average age was 70.0±9.7 years, 2331 (40.6%) were men and 3410 (59.4%) were women. The most common cardiovascular diseases were: coronary artery disease – 55.4%, HD – 22.5% and HRT – 13.5% of cases. Among concomitant diseases of non-cardiac reasons, diabetes mellitus was most often noted – in 31.5% of cases, chronic kidney disease – in 31.1% and chronic obstructive pulmonary disease – in 10% of cases. Concomitant diseases were more common in patients with CHF of functional classes III–IV. Conclusion. Maintaining a register of CHF and analyzing register data makes it possible to assess the required volume of medical care, plan the necessary time, material, economic and organizational resources and take into account possible difficulties in diagnosis, treatment and outpatient monitoring.
- Open Access
- 30 April 2022
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (5) , 5039
Optimization of intravascular volume determination in patients with acute decompensated heart failure
Acute decompensated heart failure (ADHF) is based on multilevel pathological pathways, which include hemodynamic overload and venous stasis. Determination of the volemic status is one of the most important tasks in managing such patients. Despite the availability of modern diagnostic markers (physical examination, chest x-ray, and brain natriuretic peptide (BNP) assessment), they do not accurately assess the degree of fluid overload, and therefore there remains a need to find a new, accurate and simple technology for assessing pulmonary congestion. The urgency of this problem has led to the development of a novel non-invasive remote dielectric sensing (ReDS) technology, which is a quantitative method for measuring the total volume of lung fluid by determining the tissue dielectric properties. The use of this technology makes it possible to quickly, non-invasively and quantitatively measure the fluid content in the lungs, makes it possible to optimize the treatment regimen and reduces the number of readmissions. This article presents the results of studies on the efficacy, safety and prospects for using a ReDS technology for the quantitative measurement of total lung fluid in patients with ADHF.
- 30 April 2022
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (5) , 5039
Open AccessOptimization of intravascular volume determination in patients with acute decompensated heart failure
Acute decompensated heart failure (ADHF) is based on multilevel pathological pathways, which include hemodynamic overload and venous stasis. Determination of the volemic status is one of the most important tasks in managing such patients. Despite the availability of modern diagnostic markers (physical examination, chest x-ray, and brain natriuretic peptide (BNP) assessment), they do not accurately assess the degree of fluid overload, and therefore there remains a need to find a new, accurate and simple technology for assessing pulmonary congestion. The urgency of this problem has led to the development of a novel non-invasive remote dielectric sensing (ReDS) technology, which is a quantitative method for measuring the total volume of lung fluid by determining the tissue dielectric properties. The use of this technology makes it possible to quickly, non-invasively and quantitatively measure the fluid content in the lungs, makes it possible to optimize the treatment regimen and reduces the number of readmissions. This article presents the results of studies on the efficacy, safety and prospects for using a ReDS technology for the quantitative measurement of total lung fluid in patients with ADHF.
- Open Access
- 15 January 2022
- Published by Consilium Medicum in Consilium Medicum
- Vol. 24 (1) , 7-12
Acute decompensated heart failure. What has changed in the clinical guidelines in 2021?
In September 2021, the European Society of Cardiology issued new guidelines on the management of patients with heart failure (HF). In the current version, experts have focused on the 4 most common variants: acute HF decompensation, acute pulmonary edema, cardiogenic shock, and isolated right ventricular failure. There has been a change in approaches to the initial management of patients with acute HF decompensation towards a decrease in the evidence-based use of peripheral vasodilators and a "return" to loop diuretics as the basis of treatment. This raises the question of monitoring the efficacy of diuretic therapy. The paper presents an algorithm proposed by the European Society of Cardiology.
- 15 January 2022
- Published by Consilium Medicum in Consilium Medicum
- Vol. 24 (1) , 7-12
Open AccessAcute decompensated heart failure. What has changed in the clinical guidelines in 2021?
In September 2021, the European Society of Cardiology issued new guidelines on the management of patients with heart failure (HF). In the current version, experts have focused on the 4 most common variants: acute HF decompensation, acute pulmonary edema, cardiogenic shock, and isolated right ventricular failure. There has been a change in approaches to the initial management of patients with acute HF decompensation towards a decrease in the evidence-based use of peripheral vasodilators and a "return" to loop diuretics as the basis of treatment. This raises the question of monitoring the efficacy of diuretic therapy. The paper presents an algorithm proposed by the European Society of Cardiology.